Tivantinib (ARQ 197) is an orally administered small molecule that selectively inhibits the c-Met receptor tyrosine kinase. It has demonstrated antineoplastic activity in preclinical studies, showing efficacy in both in vitro cell proliferation assays and in vivo xenograft models of various cancers, including hepatocellular and non-small cell lung carcinomas.